| |
The MIRACLE project aims at developing an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells (CTCs and DTCs) in blood. The new lab-on-chip is an essential step towards faster and cost-efficient diagnosis of cancer.
Detection of circulating and disseminated tumor cells in blood is a promising methodology to diagnose cancer dissemination or to follow up cancer patients during therapy. Today, the detection analyses of these cells are performed in medical laboratories requiring labor intensive, expensive and time-consuming sample processing and cell isolation steps. A full tumor cell detection analysis can take more than a day. A lab-on-chip, integrating the many processing steps, would enable a faster, easy-to-use, cost-effective detection of tumor cells in blood. They are therefore labor-saving and minimally invasive, increasing the patient’s comfort and the efficiency of today’s healthcare.
In a preceding joint project by some of the partners (MASCOT FP6-027652), individual microfluidic modules for cell isolation, cell counting, DNA amplification and detection have been developed. Based on this expertise and strengthened by additional partners, the development of a fully automated, lab-on-chip platform to isolate, count and genotype CTCs is envisaged within the framework of the MIRACLE project. For genotyping, genetic material (i.e. the mRNA) will be extracted from the cells and multiple cancer related markers will be amplified based on multiplex ligation dependent probe amplification (MLPA) followed by their detection using an array of electrochemical sensors. Full integration of all steps requires innovative research and processing steps that need a combination of the multidisciplinary and unique expertise of the different project partners (ranging from microfluidics to interfacing, miniaturization, and integration skills). The resulting lab-on-chip tumor detection system will be well ahead of the current state-of-the-art, revolutionizing cancer diagnostics and individualized theranostics.
Within the framework of the MIRACLE project (miracle-fp7.eu), imec as project coordinator, collaborates with the Universitat Rovira I Virgili (Spain), the Institut für Mikrotechnik Mainz, AdnaGen, ThinXXs and Consultech (Germany), MRC Holland (The Netherlands), the Oslo University Hospital (Norway), the KTH Royal Institute of Technology, Multi-D and Fujirebio Diagnostics (Sweden), ECCO - the European CanCer Organisation and ICsense (Belgium) and Labman (UK). The project aims at developing a fully automated and integrated microsystem providing the genotype (gene expression profile) of CTCs and DTCs starting from clinical samples. MIRACLE is partly funded by the European Commission (FP7-ICT-2009.3.9).
About imec
Imec (imec.be) performs world-leading research in nanoelectronics. Imec leverages its scientific knowledge with the innovative power of its global partnerships in ICT, healthcare and energy. Imec delivers industry-relevant technology solutions. In a unique high-tech environment, its international top talent is committed to providing the building blocks for a better life in a sustainable society. Imec is headquartered in Leuven, Belgium, and has offices in Belgium, the Netherlands, Taiwan, US, China and Japan. Its staff of more than 1,750 people includes over 550 industrial residents and guest researchers. In 2009, imec's revenue (P&L) was 275 million euro.
Imec is a registered trademark for the activities of IMEC International (a legal entity set up under Belgian law as a "stichting van openbaar nut”), imec Belgium (IMEC vzw supported by the Flemish Government), imec the Netherlands (Stichting IMEC Nederland, part of Holst Centre which is supported by the Dutch Government), imec Taiwan (IMEC Taiwan Co.) and imec China (IMEC Microelectronics (Shangai) Co. Ltd.).
Contact:
imec: Katrien Marent, Director of External Communications, T: +32 16 28 18 80, Mobile: +32 474 30 28 66, katrien.marent@imec.be
|
katrien.marent[.]imec.be 
